Comparing Progestin-Primed Ovarian Stimulation to GnRH Antagonist in IVF
Effectiveness of Progestin-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol for Ovarian Stimulation in IVF: a Randomized Clinical Trial
This study is testing if a new way of preparing ovaries for IVF using Progestin-Primed Ovarian Stimulation works better than the standard GnRH antagonist method for women aged 18-40.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 626 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | Female |
| Sponsor | Mỹ Đức Hospital Academic / other |
| Locations | 1 site (Ho Chi Minh City) |
| Trial ID | NCT06378268 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of Progestin-Primed Ovarian Stimulation (PPOS) compared to the GnRH antagonist protocol in women undergoing in vitro fertilization (IVF). Participants aged 18-40 will be randomly assigned to receive either PPOS or GnRH antagonist treatment, with specific dosages of recombinant FSH and dydrogesterone or cetrorelix administered during the ovarian stimulation process. The study will monitor follicular development and hormone levels to assess the outcomes of each approach.
Who should consider this trial
Good fit: Ideal candidates for this study are women aged 18-40 with a BMI of 25 or less and specific ovarian reserve indicators who are seeking IVF treatment.
Not a fit: Patients who may not benefit include those with polycystic ovary syndrome (PCOS), those undergoing different IVF protocols, or those with allergies to the study medications.
Why it matters
Potential benefit: If successful, this study could provide a more effective ovarian stimulation protocol for women undergoing IVF, potentially improving pregnancy rates.
How similar studies have performed: Other studies have shown promising results with similar ovarian stimulation approaches, indicating potential for success in this trial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Woman aged 18-40 * BMI ≤ 25kg/m2 * AMH \> 1.2ng/mL or AFC \>5 * Having indication for IVF treatment * Agree to have frozen embryo(s) transfer * Not participating in any other clinical trials * Provision of written informed consent to participate Exclusion Criteria: * Undergoing IVF cycle with other protocols: Down-regulation, mild stimulation, Random start * Oocyte donation cycles * Undergoing vitrified oocyte accumulation * Oocyte cryopreservation * Cycle with PGT (Preimplatation genetic testing) * Women with PCOS * Women allergy to dydrogesterone, rFSH, GnRH antagonist
Where this trial is running
Ho Chi Minh City
- My Duc Hospital — Ho Chi Minh City, Vietnam (Recruiting)
Study contacts
- Principal investigator: Lan N Vuong, MD, PhD — University of Medicine and Pharmacy at Ho Chi Minh City
- Study coordinator: Minh N Chau, MD
- Email: bsminh.cn@myduchospital.vn
- Phone: +84903119996
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.